Home › Funds › Catalio Capital Management, LP › BBIO

Catalio Capital Management, LP position in BBIO

BRIDGEBIO PHARMA INC · Health Care

Catalio Capital Management, LP reported holding 455,041 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q2 2026 13F filing — a position valued at US$33.9M, representing 6.37% of its reported portfolio and ranking #4 among its reported holdings. Catalio Capital Management, LP has disclosed BBIO holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

Latest position (Q2 2026)455.04K sh
Reported value held$33.89M
Portfolio Weight6.37%
First reportedQ4 2024
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Catalio Capital Management, LP's BBIO position evolved

Catalio Capital Management, LP first disclosed a stake in BBIO in Q4 2024 at 898,458 shares (US$24.7M). The position peaked in Q2 2025 at 927,711 shares, worth US$40.1M. Across 7 filings, Catalio Capital Management, LP increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 455,041 shares valued at US$33.9M — an increase of 23,027 shares quarter over quarter.. Notable position changes include a 33% trim in Q3 2025 (shares rose 47% over the following quarter), a 34% trim in Q4 2025 (shares fell 3% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 898.46K $24.65M New
Q1 2025 962.88K $33.29M Add
Q2 2025 927.71K $40.06M Reduce
Q3 2025 622.73K $32.34M Reduce
Q4 2025 410.70K $31.41M Reduce
Q1 2026 432.01K $32.08M Add
Q2 2026 455.04K $33.89M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBIO and 13F data

BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 48 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBIO

All BBIO fund holders →

FAQ

How long has Catalio Capital Management, LP held BBIO?

Catalio Capital Management, LP has disclosed BBIO holdings in 7 of the last 7 reported quarters, going back to Q4 2024.

What is Catalio Capital Management, LP's current position in BBIO?

As of Q2 2026, Catalio Capital Management, LP holds 455.04K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $33.89M, representing 6.37% of its reported portfolio and ranking #4.

Has Catalio Capital Management, LP been buying or selling BBIO?

In the latest 13F filing (Q2 2026), Catalio Capital Management, LP increased its position in BBIO. The position peaked in Q2 2025 at 927.71K shares.

Which other funds hold BBIO?

Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.